National Technical University of Athens (NTUA)
Biosynthesis and genetic selection of oligopeptides with potentially therapeutic effects against Alzheimer' s disease: inhibitors of amyloid-β aggregation
Abstract
dc:descriptionAlzheimer’s disease (AD) is the most devastating neurodegenerative disease and the most common form of dementia. So far, AD drug candidates have been deemed unable to halt disease progression and, thus, effective therapeutics are in enormous demand. The pathogenesis of AD has been strongly linked to amyloid β (Aβ), a peptide composed of 37-43 amino acids with the tendency to form neurotoxic oligomeric and aggregated structures. As a result, the discovery of small-molecule and biological inhibitors of Aβ aggregation presents an attractive therapeutic approach for the treatment of AD, which has been pursued aggressively by the pharmaceutical industry.The work presented herein describes the development of engineered bacterial cells with the ability to function as a discovery platform for chemical rescuers of Aβ misfolding and neurotoxic aggregation, with potentially therapeutic properties against AD. In this system, combinatorial libraries of cyclic peptides with extended chemical diversities are biosynthesized in Escherichia coli cells and simultaneously screened for their ability to inhibit the aggregation of Aβ, using an ultrahigh-throughput genetic assay. This assay detects bioactive cyclic peptides that enhance the fluorescence of a chimeric Αβ fusion with the green fluorescent protein (GFP). Both the fusion and the cyclic oligopeptide libraries under investigation are co-expressed in the engineered bacteria, and selection of individual, fluorescent bacterial clones is performed via fluorescence-activated cell sorting (FACS).By using this engineered system, a library of more than 10 million different short cyclic peptides was biosynthesized and rapidly screened, and hundreds of bioactive peptides with putative modulatory effects on Aβ aggregation were identified. From the isolated hits, two cyclic pentapeptides with sequences cyclo-SASPT and cyclo-TAFDR, termed AβC5-34 and AβC5-116 respectively, were acquired in isolated form, following chemical synthesis, and their effects on Αβ aggregation were investigated in a variety of biochemical, biophysical and biological assays in vitro. These analyses revealed that the selected cyclic peptides interfered with the normal course of Αβ aggregation, leading to the formation of atypical Aβ aggregates that exhibited reduced neurotoxicity compared to that of typical Αβ aggregates. The protective effects of AβC5-34 and AβC5-116 against the aggregation and cytotoxicity of Aβ were also evaluated in vivo, using established transgenic Caenorhabditis elegans models of AD, expressing human Aβ. These assays revealed that AβC5-34 and AβC5-116 exerted a protective effect against the aggregation and cytotoxicity of Aβ. Thus, AβC5-34 and AβC5-116 constitute attractive lead molecules, which upon further evaluation can aid in the development of effective anti-amyloid therapies against AD. Finally, a combination of site-directed mutagenesis and next-generation sequencing analysis of the hits derived from screening, allowed the discovery of structure-activity relationships within the selected peptide population and revealed the existence of distinct families of bioactive cyclic peptides.
Degree
thesis:*- Grantor dc:publisher
- National Technical University of Athens (NTUA)
- Year dc:date
- 2018
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Matis, Ilias
- Μάτης, Ηλίας
Subjects
dc:subject × 12Rights
dc:rights- Statement dc:rights
-
- BY_NC_ND
- Language dc:language
- eng
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/43912